M-J. Ahn

1.1k citations

68 papers · 622 indexed · h-index 14

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
Pulmonary and Respiratory Medicine top 5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment

Papers in ⓘ

Oncology 49
- Colorectal Cancer Treatments and Studies 19
- Cancer Immunotherapy and Biomarkers 18
- Lung Cancer Research Studies 14
- HER2/EGFR in Cancer Research 9
Pulmonary and Respiratory Medicine 53
- Lung Cancer Treatments and Mutations 51
- Lung Cancer Diagnosis and Treatment 6
- Gastric Cancer Management and Outcomes 6

Co-authors: Solange Peters (2 shared papers)Dongwook Kim (12 shared papers)David Planchard (6 shared papers)Pasi A. Jänne (6 shared papers)Ramona F. Swaby (3 shared papers)Byoung Chul Cho (10 shared papers)Enriqueta Felip (13 shared papers)Barbara Burtness (2 shared papers)
Journals: Annals of Oncology (55 papers)Journal of Thoracic Oncology (9 papers)ESMO Open (2 papers)Journal of Clinical Oncology (1 paper)Pneumologie (1 paper)
Partner nations: South Korea United States Spain

In The Last Decade

M-J. Ahn

67 papers receiving 617 citations

Peers

Countries citing papers authored by M-J. Ahn

Since Specialization

Citations

This map shows the geographic impact of M-J. Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M-J. Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M-J. Ahn more than expected).

Fields of papers citing papers by M-J. Ahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M-J. Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M-J. Ahn. The network helps show where M-J. Ahn may publish in the future.

Co-authors

The 25 scholars most cited alongside M-J. Ahn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M-J. Ahn Line = papers co-authored together M-J. Ahn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 68 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial Annals of Oncology ·Ezra E.W. Cohen, Kevin J. Harrington, Christophe Le Tourneau, José Dinis, Lisa Licitra, M-J. Ahn, Ainara Soria, J-P. Machiels, Nicolas Mach, Ranee Mehra, Barbara Burtness, Y. Wang, Alba Tuozzo, Ramona F. Swaby, Denis Soulières	2017	60
2	CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study Annals of Oncology ·John D. Powderly, Manish R. Patel, Jina Lee, Joshua Brody, Funda Meric‐Bernstam, Erika Hamilton, Santiago Ponce Aix, Javier García-Corbacho, Y-J. Bang, M-J. Ahn, Sun Young Rha, Kwang Pyo Kim, Marta Gil-Martín, H. Wang, Adam S. Lazorchak, Timothy Wyant, Anna Ma, Shefali Agarwal, David Tuck, Adil Daud	2017	45
3	LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial Annals of Oncology ·Keiko Goto, K. Sang-We, Takafumi Kubo, Y. Goto, M-J. Ahn, David Planchard, Dongwook Kim, J.C-H. Yang, T-Y. Yang, Kaline Pereira, Kapil Saxena, Ryota Shiga, Yun Cheng, Mehreteab Aregay, Pasi A. Jänne	2022	44
4	OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial Journal of Thoracic Oncology ·Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth, K.H. Lee, Alexander Luft, M-J. Ahn, Vassiliki A. Papadimitrakopoulou, John V. Heymach, Urban Scheuring, Brandon W. Higgs, Jiabu Ye, Michael Kuziora, Song Wu, F. Liu, Han Si, Solange Peters	2019	43
5	Gefitinib/Chemotherapy Vs Chemotherapy in Epidermal Growth Factor Receptor (Egfr) Mutation-Positive Non-Small-Cell Lung Cancer (Nsclc) After Progression on First-Line Gefitinib: the Phase Iii, Randomised Impress Study Annals of Oncology ·Tony Mok, Yujun Wu, Ken Nakagawa, S. Kim, J. Yang, M-J. Ahn, J. Wang, J. Yang, Yushuang Lü, Shinji Atagi, Santiago Ponce, Xiaoliang Shi, Alan Webster, Hong Jiang, J.C. Soria	2014	38
6	93TiP MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy Journal of Thoracic Oncology ·David R. Spigel, Solange Peters, M-J. Ahn, Masahiro Tsuboi, Jamie E. Chaft, David H. Harpole, Fabrice Barlési, Christopher Abbosh, Helen Mann, R. May, P. Dennis, Charles Swanton	2021	38
7	LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 Annals of Oncology ·M-J. Ahn, Aaron Lisberg, Luis Paz‐Ares, Robin Cornelissen, Nicolas Girard, Elvire Pons‐Tostivint, David Vicente Baz, Shunichi Sugawara, Manuel Cobo, M. Pérol, Céline Mascaux, Elena Poddubskaya, Satoru Kitazono, Hidetoshi Hayashi, Jacob Sands, Richard D. Hall, Yong Zhang, Hong Zebger‐Gong, Deise Uema, Isamu Okamoto	2023	34
8	1314MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) Annals of Oncology ·Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg, Satoru Kitazono, B.C. Cho, George R. Blumenschein, Elaine Shum, E. Pons-Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, Paul Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, Hong Zebger‐Gong, Lei Lan, C. Liu, Jacob Sands	2023	30
9	1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC Annals of Oncology ·M-J. Ahn, Jiaxin Niu, Dongwook Kim, Drew Rasco, Kathryn F. Mileham, Hyun Cheol Chung, Ulka N. Vaishampayan, Corinne Maurice‐Dror, Piere Russo, Talia Golan, Elliot Chartash, D. Chen, Jane Healy, Mohini Rajasagi, D.H. Lee	2020	26
10	858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) Annals of Oncology ·Anthony T.�C. Chan, Victor Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S-B. Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, M.A.S. Abdul Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, K.C. Ngan, S.K. Kho, Ramona F. Swaby, Sanatan Saraf, Joy Yang Ge, L.L. Siu	2021	24
11	1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC Annals of Oncology ·Jiaxin Niu, Adnan Nagrial, Mark Voskoboynik, Hyun Cheol Chung, D.H. Lee, M-J. Ahn, Todd M. Bauer, Antonio Jimeno, Vincent Chung, Kathryn F. Mileham, Elliot Chartash, D. Chen, Jane Healy, Mohini Rajasagi, Corinne Maurice‐Dror	2020	19
12	LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial Annals of Oncology ·M-J. Ahn, S-W. Kim, Enric Carcereny, Laura Rodríguez, Jorge Oliveira, M.A. Insa Molla, Margarita Majem, Luís Costa, Wu‐Chou Su, K.H. Lee, James Chih‐Hsin Yang, David R. Spigel, E.K. Cho, M. D’Arcangelo, M.R. García Campelo, Angelo Delmonte, P. Mitchell, Ikbel Achour, Deepa S. Subramaniam, Enriqueta Felip	2022	15
13	Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies Annals of Oncology ·Tetsuya Mitsudomi, M-J. Ahn, Lyudmila Bazhenova, Fiona Blackhall, Toyoaki Hida, M. Majem Tarruella, Sarah L. Vowler, Gianluca Laus, Pasi A. Jänne, J.C-H. Yang	2017	14
14	Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis Annals of Oncology ·J.C. Soria, Soo Wan Kim, Yi‐Long Wu, Kazuhiko Nakagawa, Jin‐Ji Yang, M-J. Ahn, J. Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce Aix, Yuri Rukazenkov, Rosemary Taylor, Tony Mok	2016	13
15	4O First-line (1L) osimertinib (osi) ± platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: FLAURA2 post-progression outcomes ESMO Open ·Natalia Valdiviezo, Isamu Okamoto, Brett Hughes, S. Ahmed, Lin Wu, Jie Hu, Ronald D. Alvarez, Ki Hyeong Lee, Satoshi Oizumi, Xuan Dung Pham, Rohan Bhise, M-J. Ahn, Glaucio Bertollo, Yuichi Tambo, R.K. Li, A. Todd, D. Kulkarni, Neha P. Amin, David Planchard, Pasi A. Jänne	2024	13
16	Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC Annals of Oncology ·Fabrice Barlési, Edward B. Garon, Dongwook Kim, Enriqueta Felip, J. Y. Han, Jin‐Hoi Kim, M-J. Ahn, Mary J. Fidler, Matthew A. Gubens, G. Castro, Veerle Surmont, Q. Li, Anne C. Deitz, Gregory M. Lubiniecki, Roy S. Herbst	2016	9
17	A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC Annals of Oncology ·Alexander Drilon, Stephen V. Liu, Robert C. Doebele, Cristina P. Rodriguez, Marwan Fakih, Karen L. Reckamp, Lyudmila Bazhenova, B.C. Cho, E. Kowack, Jennifer Oliver, Pratik S. Multani, M-J. Ahn	2017	9
18	364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases Annals of Oncology ·Thomas John, C-H. Chiu, B.C. Cho, Marwan Fakih, Anna F. Farago, George D. Demetri, Keiko Goto, Robert C. Doebele, Salvatore Siena, Alexander Drilon, Manish R. Patel, Stephen V. Liu, M-J. Ahn, Lyudmila Bazhenova, Tobias R. Overbeck, Jorge J. Nieva, S-W. Kim, L. Véronèse, B-M. Day, Filippo de Braud	2020	9
19	518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) Annals of Oncology ·Satoru Kitazono, Luis Paz‐Ares, M-J. Ahn, Aaron Lisberg, Byoung Chul Cho, George R. Blumenschein, Elaine Shum, E. Pons-Tostivint, Yasushi Goto, Kiyotaka Yoh, Rebecca S. Heist, Paul Baas, David Planchard, M. Pérol, Enriqueta Felip, Wu‐Chou Su, Hong Zebger‐Gong, Lei Lan, C. Liu, Jacob Sands	2023	8
20	MS28.02 Combination IO+IO Journal of Thoracic Oncology ·M-J. Ahn	2018	7

About M-J. Ahn

M-J. Ahn is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Otorhinolaryngology, Gastroenterology and Genetics, having authored 68 papers that have together received 622 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (51 papers), Colorectal Cancer Treatments and Studies (19 papers), Cancer Immunotherapy and Biomarkers (18 papers), Lung Cancer Research Studies (14 papers), HER2/EGFR in Cancer Research (9 papers), Cancer Genomics and Diagnostics (6 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Gastric Cancer Management and Outcomes (6 papers). The work is most often cited by research in Oncology (517 citations), Pulmonary and Respiratory Medicine (394 citations), Otorhinolaryngology (47 citations), Cancer Research (93 citations) and Immunology (105 citations). M-J. Ahn has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include Solange Peters, Dongwook Kim, David Planchard, Pasi A. Jänne, Ramona F. Swaby, Byoung Chul Cho, Enriqueta Felip, Barbara Burtness, José Dinis and David R. Spigel. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, ESMO Open, Journal of Clinical Oncology and Pneumologie.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact